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Abstract
Melanoma is among the leading causes of years of life lost due to cancer. Current chemotherapy and
cytokine-based immunotherapy approaches benefit only a small percentage of patients with advanced
disease. However, the recent discovery of mutations in the gene encoding the serine-threonine
kinase B-RAF (BRAF) raises the possibility that oncogene-targeted therapy may provide a new point of
vulnerability. In parallel, a deeper understanding of the molecular mechanisms underlying antitumor
T-cell activation and tolerance has provided a basis for developing therapies targeted against these
processes. Results from an early phase trial with a BRAF inhibitor and a phase III trial with a novel
agent that activates T cells have radically altered the prospects for improving outcomes for patients
with this historically treatment-refractory disease.
Introduction
Melanoma is one of the most devastating forms of cancer
in terms of the number of years of life that patients lose,
as it often affects younger people compared with other
types of tumor. As with other cancers, chemotherapy
has remained the mainstay of treatment for over half
a century. The shortcomings of this approach are all
too clear: when treated with chemotherapy, a diagnosis
of metastatic melanoma generally meant a relentless
progressive disease and death in approximately 6–9
months. Even immunotherapy, which has an accepted
role in the treatment of metastatic melanoma patients, as
well as those who have regional lymph node involve-
ment that has been excised but remains at high risk of
recurrence, fails to benefit more than a small minority
of patients. Clearly, there is a need for a more effective
treatment, and recently two more targeted approaches
have begun to show great promise and hopefully will
change the therapeuticlandscape for melanoma. The first
of these is the emergence of selective inhibitors of the
serine-threonine protein kinase B-RAF (BRAF) for the
treatment of metastatic melanoma, which have shown
dramatic results in the 50% of patients whose tumors
harbor an activating mutation in the oncogene encod-
ing this kinase, BRAF, at least temporarily reversing the
growth of the melanoma, resulting in a potential benefit in
terms of life expectancy. Also, recent clinical trial results
with novel immunologic therapies appear to be break-
ing the barriers observed with the previous generation of
cytokine-based immunotherapies, and have produced
some dramatic results. This review examines these devel-
opments in detail and discusses waysto improvetreatment
further.
Oncogene-targeted therapy
The identification of activating mutations in BRAF in
50–60% of melanomas in 2002 was the watershed event
that opened the door for investigation of molecularly
targetedtherapyinmelanoma[1].BRAFisaconstituentof
the long-studied mitogen-activated protein (MAP) kinase
pathway, a well-known mediator of growth factor signals
in cancer. Therefore, when BRAF mutations were found in
a large series of diverse tumor types, it was immediately
apparent that these mutations might explain the involve-
ment of this pathway in 7–8% of all cancers. As BRAF
mutations are found most commonly in melanoma,
laboratory investigation and clinical development of
BRAF-targeted therapies naturally focused on this disease.
Thefundamentalchallengesthatconfrontedthefieldwere
to understand why BRAF might be the tumors’ Achilles
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genetic alterations, and to develop potent and selective
inhibitors.
For several years following the identification of BRAF
mutations, sorafenib was the only targeted therapy in
clinical development known to have some capacity for
inhibiting RAF kinases. However, in phase II trials,
sorafenib demonstrated only moderate MAP kinase path-
way inhibition and little to no clinical efficacy as a single
agent [2,3]. However, this moderate inhibition gave
hope that more potent and selective BRAF inhibitors
might yield better results, and consequently several BRAF
inhibitors have entered clinical trials within the past few
years. As PLX4032 and GSK2118436 are the first selective
BRAF inhibitors to show an effect in patients, I will focus
mainly on them.
In light of preclinical data demonstrating that PLX4032
had selective antitumor effects in tumors harboring BRAF
mutations,and becauseofthe frequencywithwhichBRAF
mutations are known tooccur inmelanoma, 49out ofthe
55patientswithvarioustypesoftumorwhowereenrolled
during the dose escalation phase of the small preliminary
phase I clinical trial of PLX4032 had metastatic mela-
noma, and after the first evidence of measurable reduc-
tions in tumor size, the majority of patients enrolled
had BRAF-mutant metastatic melanoma, which, rather
unusually for a phase I trial, allowed not only for the
characterization of safety and tolerability, but also efficacy
[4].ItwasapparentthatthedrugonlyworkedintheBRAF-
mutant melanoma patients. As the dose was escalated to
find the maximum tolerated dose, an increasing percen-
tage of patients responded. By the time the highest five
doselevelswereevaluated,11ofthe16patientsharboring
the mutation experienced an objective response according
to RECIST (Response Evaluation Criteria In Solid
Tumors). All but two of these had at least some evidence
of tumor regression. Dose-dependent toxicities that were
commonly observed at the higher doses included rash
fatigue, arthralgia, and photosensitivity. Severe rash,
fatigue, and arthralgia ultimately dictated the maximum
tolerated dose, but could be managed by interrupting
therapy, when necessary, or with dose reduction.
Ultimately, 32 additional patients with BRAF-mutant
metastatic melanoma were enrolled in the extension
phase of the trial and given a dose of 960 mg twice daily.
A total of 81% of these patients showed measurable
reduction in tumor size, two of these were tumor free,
and four additional patients had minor degrees of tumor
regression. Progression-free survival for these patients
was generally greater than 7 months but it is too early to
define overall survival. As a side effect, nearly one-third
of these patients developed one or more skin lesions—
either well-differentiated squamous cell carcinoma or
keratoacanthoma. This finding is not so surprising: it has
been known for many years that a subset of squamous
cell carcinomas and keratoacanthomas harbor mutations
in the gene encoding HRAS (a member of the RAS family
of small GTPases), and more recently it has been
observed that selective BRAF inhibitors induce MAP
kinase pathway signaling, particularly in the setting of
RAS mutations. It seems likely that these two factors
interact to cause the appearance of these lesions during
therapy. The clinical significance of squamous cell
carcinomas and keratoacanthomas seems marginal in
the setting of treatment for metastatic melanoma as they
can be easily treated in most cases, but warrants more
careful study.
The second BRAF inhibitor, GSK2118436, was evaluated
in a phase I clinical trial [5] of similar design to the
PLX4032 study, and the results were even more striking.
GSK2118436is evenmorepotent ininhibitingBRAFthan
PLX4032 and is able to inhibit mutant BRAF kinase
activity by 50% at concentrations less than 1 nM. A total
of 93 patients were enrolled during the dose escalation
portion of the trial, 85 of whom had metastatic
melanoma, and of those, 76 had activating mutations in
BRAF. Doses ranged from 12 mg daily to 400 mg daily. At
the highest dose, dose-limiting toxicities were severe
pyrexia and loss of consciousness. Among 35 patients
treated at one of these two highest dose levels, the most
common toxicities were pyrexia, fatigue, rash, the appear-
ance of squamous cell carcinomas and keratoacanthomas,
headache, nausea, and vomiting. Among the 16 patients
treated at the two highest dose levels, there were 10
measurable responses observed (63% response rate).
GSK2118436onlyfailedtohalttumorgrowthprogression
intwopatientstreatedatthehigherdoselevelsatorbefore
the first restaging evaluation. Of the nine patients who
were enrolled with V600K mutations in BRAF,f o u rh a d
measurable responses. In addition to seeing responses in
all visceral sites, treatment reduced the size of small,
asymptomatic, previously untreated brain metastases in
all of the subgroups of patients with this condition.
Taken together, the early clinical development of
PLX4032 and GSK2118436 clearly confirm that BRAF
inhibitors can (at least temporarily) halt or reverse
disease in patients with melanomas carrying this muta-
tion, apparently improving survival times compared
with historically standard treatments (chemotherapy and
interleukin-2), although the follow-up times are still
too short to define median overall survival times. Even
more dramatic results may be possible with further
refinements.
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Antitumor immune therapy has also taken a leap forward
recently, following a breakthrough in understanding T-cell
activation and anergy. Cytotoxic T-lymphocyte antigen 4
(CTLA4) is a T-cell surface receptor that competes with
CD28 to bind with (T-cell stimulatory) B7 molecules
on the surface of antigen presenting cells and promotes
anergy. When the CD28:CTLA4 ratio is high, T-cell
activation ensues, whereas anergy is the result of a low
ratio. Thus an antibody targeting CTLA4 allows the B7/
CD28interfacetocontinuetodriveT-cellactivation,rather
than become anergic, and this approach has been tested
in the clinic in series of clinical trials spanning the past
10 years. The furthest advanced of this generation of
therapies is ipilimumab, the CTLA4-blocking antibody
that was recently shown to increase survival in metastatic
melanoma patients in a (larger) phase III trial.
Although measurable responses were only seen in
10% of patients, or slightly less, proof-of-concept was
established early on [6,7] in small trials based on the
durability of these responses. Some patients with
advanced metastatic disease who had failed other
therapies could be stabilized for months or even several
years. However, a phase III trial was clearly needed to
define the true size of the subpopulation that would
benefit. In the first of these trials to be analyzed [8],
patients with metastatic melanoma who had failed
standard therapy such as dacarbazine were randomly
assigned to receive ipilimumab in combination with a
gp-100 peptide vaccine, ipilimumab alone, or peptide
vaccine alone [8]. Because the gp-100 peptide can only
be recognized by the human leukocyte antigen (HLA)
marker HLA-A2, all patients were required to have this
HLA type. Patients were randomly assigned such that
60% received ipilimumab/gp-100, 20% received ipili-
mumab, and 20% received the gp-100 vaccine alone. At
the time of analysis, both of the ipilimumab-treated
groups had a significantly improved survival compared
to the control group. This difference was best shown
when looking at longer follow-up time, such as two years
after initiation of study therapy (24% survival rate for
ipilimumab alone versus 14% with vaccine alone).
There are two features of this approach that are unique
compared to other standard cancer therapies. First, some
patients receiving ipilimumab have radiographic evi-
dence of disease progression during treatment, receive
no subsequent therapy, and then manifest measurable
responses months later. Amongst patients who demon-
strate disease progression following the initial course of
therapy (typically 3 months), there is a small percentage
who will subsequently benefit. However, it is not
currently possible to prospectively distinguish between
patients who will experience unchecked progression
and those with a delayed response to therapy. Second,
ipilimumab induces activation not only of T cells that are
capable of recognizing melanoma, but also of those
recognizing self antigens, resulting in autoimmunity.
A large percentage of patients develop some sort of mild
or moderate autoimmunity in the first several months of
therapy, requiring only minimal supportive care mea-
sures. The skin and gastrointestinal tract are the most
common organs involved, manifesting as rash or
diarrhea, but sometimes endocrine glands are involved.
Severe diarrhea leading to dehydration and electrolyte
deficiencies is a concern, but not as much as (rarer)
gastrointestinal perforation. Amongst the endocrinopa-
thies, the most clinically concerning is inflammation of
the pituitary gland, which can lead to permanent adrenal
insufficiency and hypothyroidism, and requires chronic
mineral-corticoid and thyroid hormone replacement
therapy. However, the life-prolonging benefit of this
therapy is clear from the recently published randomized
phase III trial, and outweighs these autoimmune side
effects.
Altered landscape
Significant advances have been made in understanding
the molecular pathophysiology, underlying genetic
causes of tumors, and mediators of antitumor T-cell
anergy. This has allowed the development of pharmaco-
logic agents to specifically counter these processes. Even
amongst patient populations with advanced, refractory
melanomas, there is clear evidence of tumor regression
and improved life expectancy with oncogene-inhibitors
and T-cell stimulatory therapies. BRAF inhibition only
works in those whose tumors harbor a BRAF mutation
(approximately 50% of all melanomas), but induces
responses in the vast majority of patients. Unfortunately,
melanomas seem to develop resistance with prolonged
treatment.
Ipilimumab, and other less-well-defined novel immu-
nologic agents, are very effective in a small subgroup of
patients, greatly extending life for these individuals, but
as yet we don’t understand the biological basis that
predicts response. With this success as a basis to build on,
it can be hoped that combinations of these and other
approaches will confer more than temporary respite
from metastatic melanoma in the future and provide
long-term benefits to a higher proportion of patients.
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